Amivantamab‐vmjw, a bispecific antibody targeting EGFR and MET receptors, initially received approval for the treatment of advanced NSCLC with EGFR exon 20 insertion mutations in patients who had progressed following platinum‐based chemotherapy (PBC) [18]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.